Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. news
  3. molecular diagnostics
Show results for

Refine by
Date

  • Older

Molecular Diagnostics Articles & Analysis

119 news found

Alfa Chemistry Provides Customized Synthesis Services for Biotinylation Reagents   

Alfa Chemistry Provides Customized Synthesis Services for Biotinylation Reagents  

This technique plays a crucial role in various research fields, including molecular biology, biochemistry, and diagnostics. With its expertise in chemical synthesis, Alfa Chemistry has become a proven and reliable provider of biotinylation reagents for scientists and researchers worldwide. ...

ByAlfa Chemistry


Medical Equipment Pump Solutions

Medical Equipment Pump Solutions

Medical Equipment Pump Solutions Industry Overview IVD, which stands for in vitro diagnostics, refers to products that conduct testing on samples taken from the human body (such as blood, body fluids, and tissues) outside of the body in order to obtain clinical diagnostic information. The IVD industry is subdivided into various sectors including ...

ByTops Industry & Technology Co.,Ltd.


Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use

Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use

More and more studies have shown that R-phycoerythrin (R-PE) labeled proteins have broad application prospects in laboratory applications, biopharmaceutical and diagnostic technologies, as well as biological imaging. For cell and molecular biology research, R-PE labeled protein can be used as a biomarker in cellular immune analysis, and can also be used as a ...

ByCreative BioMart


FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)

FPI Explores the Future of Cognitive Healthcare at the 87th China International Medical Equipment Fair (CMEF)

The SFLO series is applicable to a wide range of laboratory applications, including blood, tumour, immunophenotyping, pharmacology testing, cell biology analysis, bioengineering, pharmacology, medical research, haematology, analysis of intracellular antigenic substances, biosafety testing, blood and cell analysis, and tumour cell DNA/RNA content analysis.At this year's exhibition, FPI actively ...

ByFocused Photonics Inc. (FPI)


BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring

BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring

BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to ...

ByBioMark Diagnostics Inc.


Roswell Biotechnologies Forms Scientific Advisory Board

Roswell Biotechnologies Forms Scientific Advisory Board

Roswell Biotechnologies, Inc., the molecular electronics company, announced today the formation of its Scientific Advisory Board (SAB). ...

ByRoswell Biotechnologies Inc


Roswell Biotechnologies and Imec to Develop First Molecular Electronics Biosensor Chips for Infectious Disease Surveillance, Precision Medicine and DNA Storage

Roswell Biotechnologies and Imec to Develop First Molecular Electronics Biosensor Chips for Infectious Disease Surveillance, Precision Medicine and DNA Storage

Roswell Biotechnologies, Inc., the leader in molecular electronics sensor chips, and imec, a world-leading research and innovation hub in nanoelectronics and digital technologies, announced today a partnership to develop the first commercially available molecular electronics biosensor chips. These chips are the brains behind Roswell Technologies' powerful new ...

ByRoswell Biotechnologies Inc


Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch

Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch

The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 – 12 months based on the completion of the ISO 15-189 certification. About BioMark Diagnostics Inc. BioMark is a liquid biopsy company developing a molecular ...

ByBioMark Diagnostics Inc.


Biomark provides business update and second quarter financial results

Biomark provides business update and second quarter financial results

Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) ...

ByBioMark Diagnostics Inc.


BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy

BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy

Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in ...

ByBioMark Diagnostics Inc.


Berkshire and Surrey Pathology Services & ONCODNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK

Berkshire and Surrey Pathology Services & ONCODNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK

DR NADINE COLLINS, CONSULTANT CLINICAL SCIENTIST IN MOLECULAR DIAGNOSTICS WHO IS BASED AT ROYAL SURREY NHS FOUNDATION TRUST, WHICH IS PART OF BERKSHIRE AND SURREY PATHOLOGY SERVICES RESPONDED: “We are part of a large Pathology organisation based at an NHS Trust that hosts a tertiary cancer referral centre. As such, the Molecular ...

ByOncoDNA S.A.


Anavasi Diagnostics Announces New Additions to Leadership Team

Anavasi Diagnostics Announces New Additions to Leadership Team

Anavasi Diagnostics ('Anavasi'), a medical technology company focused on the development of novel molecular diagnostic testing, recently announced the addition of a Chief Financial Officer, Chief Operating Officer and Chief Commercial Officer to its management roster. ...

ByAnavasi Diagnostics


BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen

BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen

BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. ...

ByBillionToOne Inc.


Mammoth Biosciences Named as an “Endpoints 11” Most Promising Startup of 2022

Mammoth Biosciences Named as an “Endpoints 11” Most Promising Startup of 2022

We continue making progress in realizing our mission to empower patients with access to one-time permanent cures made possible by next-generation in vivo therapeutics, and democratizing disease detection with next-generation molecular diagnostics.” This marks John Carroll’s 20th year selecting top private biotechs for special recognition. ...

ByMammoth Biosciences, Inc.


The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology

The US Patent Office Grants BIOMARK Additional Patent for its LIQUID BIOPSY Technology

Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel ...

ByBioMark Diagnostics Inc.


CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic

CDRD Launches New Company Developing Life-Saving Sepsis Diagnostic

The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims more lives than any cancer. Infectious disease testing (including sepsis) is one of the fastest growing molecular ...

BySepset Biosciences Inc.


Biomark to present validation data of its multianalyte metabolite panel for lung cancer screening at the esmo congress 2022

Biomark to present validation data of its multianalyte metabolite panel for lung cancer screening at the esmo congress 2022

Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it’s abstract titled “Metabolomic Profiling for the Early Detection of Lung ...

ByBioMark Diagnostics Inc.


Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

(“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel ...

ByInterpace Biosciences


Molecular Health receives IVDR certification for MH Guide

Molecular Health receives IVDR certification for MH Guide

Molecular Health, an international biotech IT company based in Heidelberg, Germany, has received European Union certification for its MH Guide clinical decision support software (SaaS) under the new In Vitro Diagnostics Regulation (EU) 2017/746 (IVDR). The MH Guide software, which is used in molecular pathology laboratories, is the first of its ...

ByMolecular Health GmbH


HiberGene Diagnostics introduces brand new UK division at NEQAS event

HiberGene Diagnostics introduces brand new UK division at NEQAS event

HiberGene Diagnostics, the leading manufacturer of molecular diagnostics products in Ireland, is pleased to announce that it will supply its innovative point-of-care (POC) and near-patient testing solutions directly to healthcare providers in the UK and Ireland. ...

ByHiberGene Diagnostics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT